Navigation Links
Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
Date:8/18/2009

WELLESLEY HILLS, Mass., Aug. 18 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.

The PRX-08066 is a Therapeutics Program in Phase 2 for respiratory indication. It is a small molecule, oral 5HT2b antagonist for potential treatment of pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD). There is significant reduction in SPAP in conditioned athletes (hypoxia challenge) and in subjects with PH/COPD. There is potential indication for pulmonary arterial hypertension (PAH) including in diastolic dysfunction.

The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, In
'/>"/>

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- The third edition of Infusion ... published by the Infusion Nurses Society (INS), includes ... Anthracyclines are a group of chemotherapy medications ... been used in the treatment of various types ... ,, According to the INS publication: "In September ...
(Date:12/14/2009)... Nektar Therapeutics (Nasdaq: NKTR ) ... to serve on its board of directors. ... over 35 years of experience in corporate management, ... Nektar extensive industry perspective at an important time ... President and CEO of Nektar and member of ...
(Date:12/14/2009)... December 14 , - ... of,Women With Rheumatoid Arthritis in Seven Major Industrialized Countries , ... with rheumatoid arthritis say their disease, ... - Women living with rheumatoid arthritis find shopping for ... cards and wrapping presents most, ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
Breaking Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2
... , , , , , , Cells ... General , Keep an eye on your cells; ensure they are ... beginning to, the end of transfection. , , ... Dividing cells tend to be more accessible for uptake and expression of, foreign ...
... , , , , , ... expression profiling technology. Agencourt offers , a cost-effective outsourcing solution for ... technology more accessible to researchers. Agencourt's , SAGE sequencing service provides ... Rapid turnaround , , ...
... , , , , ... system that can be completed in less than 15 minutes. , ... plasmid DNA directly from overnight cultures, which can improve ... by as much as a full day. SprintPreps , ...
Other Biology Technology:General Considerations for Successful Transfection Experiments 2SAGE & LONGSAGE SEQUENCING 2SPRINTPREP SINGLE STEP PLASMID PURIFICATION 2SPRINTPREP SINGLE STEP PLASMID PURIFICATION 3
(Date:12/14/2009)... of researchers from the Astrobiology Centre (INTA-CSIC) has shown ... to the formation of the most basic biological molecules ... order to carry out this study, published in the ... the chemical conditions of the early Earth. , "We ... ammoniac solutions it produces hydrogen cyanide, a substance that ...
(Date:12/14/2009)... WAYNE, Pa., Dec. 14 MODA Technology ... monitoring (EM), utility and product testing for the ... MODA 3.0, the company,s third generation mobile data ... (QC) organizations to further automate their regulated manufacturing ... new capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... have resolved a question about how a popular ... using biosensors that reveal previously hidden components of ... delusions and hallucinations characterize the illness, people with ... information in a particular order, difficulties that interfere ... function well, said Lee Schroeder, a student in ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 1Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 2Microbridge Technologies Announces Micro Flow Differential Pressure Sensors for Medical Respiration and Industrial HVAC Applications 48144 1Microbridge Technologies Announces Micro Flow Differential Pressure Sensors for Medical Respiration and Industrial HVAC Applications 48144 2Microbridge Technologies Announces Micro Flow Differential Pressure Sensors for Medical Respiration and Industrial HVAC Applications 48144 3Generic Erosion Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by 241 8 Billion from 2008 to 2018 48141 1Generic Erosion Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by 241 8 Billion from 2008 to 2018 48141 2
... the causes and treatment of asthma and Chronic Obstructive ... drugs to battle these debilitating conditions. , The ... awarded a total of 1.24m in grants to study ... Knox and Dr Linhua Pang 700,000 to research transcriptional ...
... and livestock producers have created a symbiotic relationship. Cattle ... the ethanol distilling process, giving ethanol producers have an ... Kansas State University has found that cattle fed distiller,s ... in their hindgut. This particular type of E. coli ...
... NY -- Confused about the right planting depth for ... some flower bulbs are actually "smart" enough to adjust ... published in the Journal of the American Society for ... position by moving deeper into the ground, apparently in ...
Other Biology News:HATS off to combat asthma 2K-State researchers findings on E. coli 2'Smart' flower bulbs pull themselves to deeper ground 2
WD-repeat protein 4...
... omental preadipocytes are isolated ... healthy donors. There is ... cells. Please inquire for ... also available. Academic discounts ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: